156 related articles for article (PubMed ID: 36202996)
1. CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II-III colorectal carcinoma.
Brunac AC; Fourquet J; Perot G; Jaffrelot M; Meilleroux J; Danjoux M; Filleron T; Nicolaï V; Guimbaud R; Icher S; Farés N; Selves J; Chibon F
Mod Pathol; 2022 Dec; 35(12):2002-2010. PubMed ID: 36202996
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.
Le Guellec S; Lesluyes T; Sarot E; Valle C; Filleron T; Rochaix P; Valentin T; Pérot G; Coindre JM; Chibon F
Ann Oncol; 2018 Aug; 29(8):1828-1835. PubMed ID: 29860427
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
4. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
[TBL] [Abstract][Full Text] [Related]
5. The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas.
Croce S; Lesluyes T; Valle C; M'Hamdi L; Thébault N; Pérot G; Stoeckle E; Noël JC; Fontanges Q; Devouassoux-Shisheboran M; Querleu D; Guyon F; Floquet A; Chakiba C; Mayeur L; Rebier F; MacGrogan GM; Soubeyran I; Le Guellec S; Chibon F
Clin Cancer Res; 2020 Feb; 26(4):855-861. PubMed ID: 31796515
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.
Morris JS; Luthra R; Liu Y; Duose DY; Lee W; Reddy NG; Windham J; Chen H; Tong Z; Zhang B; Wei W; Ganiraju M; Broom BM; Alvarez HA; Mejia A; Veeranki O; Routbort MJ; Morris VK; Overman MJ; Menter D; Katkhuda R; Wistuba II; Davis JS; Kopetz S; Maru DM
Clin Cancer Res; 2021 Jan; 27(1):120-130. PubMed ID: 33109741
[TBL] [Abstract][Full Text] [Related]
9. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
[TBL] [Abstract][Full Text] [Related]
10. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
11. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery.
Huang M; He J; Lai W; Liu L; Xu H; Zeng Y; Lan Q; Lin X; Chu Z
BMC Gastroenterol; 2022 Feb; 22(1):87. PubMed ID: 35227194
[TBL] [Abstract][Full Text] [Related]
12. CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond.
Chibon F; Lesluyes T; Valentin T; Le Guellec S
Genes Chromosomes Cancer; 2019 Feb; 58(2):124-129. PubMed ID: 30387235
[TBL] [Abstract][Full Text] [Related]
13. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtyping improves prognostication of Stage 2 colorectal cancer.
Purcell RV; Schmeier S; Lau YC; Pearson JF; Frizelle FA
BMC Cancer; 2019 Nov; 19(1):1155. PubMed ID: 31775679
[TBL] [Abstract][Full Text] [Related]
15. A recurrence-predictive model based on eight genes and tumor mutational burden/microsatellite instability status in Stage II/III colorectal cancer.
Gao Z; Wan Z; Yu P; Shang Y; Zhu G; Jiang H; Chen Y; Wang S; Lei F; Huang W; Zeng Q; Wang Y; Rong W; Hong Y; Gao Q; Niu P; Zhai Z; An K; Ding C; Wang Y; Gu G; Wang X; Meng Q; Ye S; Liu H; Gu J
Cancer Med; 2024 Jan; 13(1):e6720. PubMed ID: 38111983
[TBL] [Abstract][Full Text] [Related]
16. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of perineural invasion in stages II and III colorectal cancer.
Zhou Y; Wang H; Gong H; Cao M; Zhang G; Wang Y
Pathol Res Pract; 2015 Nov; 211(11):839-44. PubMed ID: 26429129
[TBL] [Abstract][Full Text] [Related]
18. RNA sequencing validation of the Complexity INdex in SARComas prognostic signature.
Lesluyes T; Pérot G; Largeau MR; Brulard C; Lagarde P; Dapremont V; Lucchesi C; Neuville A; Terrier P; Vince-Ranchère D; Mendez-Lago M; Gut M; Gut I; Coindre JM; Chibon F
Eur J Cancer; 2016 Apr; 57():104-11. PubMed ID: 26916546
[TBL] [Abstract][Full Text] [Related]
19. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer.
Coebergh van den Braak RRJ; Ten Hoorn S; Sieuwerts AM; Tuynman JB; Smid M; Wilting SM; Martens JWM; Punt CJA; Foekens JA; Medema JP; IJzermans JNM; Vermeulen L
BMC Cancer; 2020 Sep; 20(1):850. PubMed ID: 32887573
[TBL] [Abstract][Full Text] [Related]
20. A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
Piskol R; Huw L; Sergin I; Kljin C; Modrusan Z; Kim D; Kljavin N; Tam R; Patel R; Burton J; Penuel E; Qu X; Koeppen H; Sumiyoshi T; de Sauvage F; Lackner MR; de Sousa E Melo F; Kabbarah O
Clin Cancer Res; 2019 Jul; 25(14):4431-4442. PubMed ID: 31004000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
